<DOC>
	<DOCNO>NCT01944982</DOCNO>
	<brief_summary>To determine safety profile immunotherapy natural killer cell activate expand ( NKAEs ) salvage chemotherapy relapsed/refractory paediatric T cell lymphoblastic leukaemia lymphoma .</brief_summary>
	<brief_title>Salvage Therapy With Chemotherapy Natural Killer Cells Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Patients age 0 21 year relapse refractary acute lymphoblastic leukemia Tcell lymphoblastic lymphoma . Lansky Index &gt; 60 % . Left ventricular ejection fraction &gt; 39 % . Negative HIV serology . Provide inform consent accordance current legislation . Patients history poor compliance . Patients valid psychosocial evaluation Severe ( 4 ) functional organ disorder ( hepatic , renal , respiratory ) accord NCI CTCAE v3 criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>NKAEs</keyword>
	<keyword>Expanded haploidentical natural killer cell</keyword>
	<keyword>Activated natural killer cell</keyword>
</DOC>